← Back to all articles
PharmacologyPubMed VerifiedOpen Access

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial

Mueller MJ, Aicher HD, Dornbierer DA, Marten L, Suay D, Meling D, Elsner C, Wicki IA, Mueller J, Poetzsch SN, Caflisch L, Hempe A, Steinhart CP, Puchkov M, Kost J, Landolt HP, Seifritz E, Quednow BB, Scheidegger M

International Journal of Neuropsychopharmacology (2024)

Randomized controlled trial
Abstract

First RCT characterizing the pharmacokinetics and pharmacodynamics of a standardized oral DMT/harmine formulation (ayahuasca analogue). Established dose-response relationships for subjective, cardiovascular, and neuroendocrine effects. Enables standardized dosing for future clinical trials.

Participants30
Citations10
Study TypeRandomized controlled trial
pharmacokineticspharmacodynamicsDMTharminestandardized formulationdose-response
DOI: 10.1093/ijnp/pyaf001View on PubMed

Related Articles

Pharmacology

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans

Wittayakarn N, Tan YM et al.

Toxicological Sciences, 2025
Pharmacology

Pharmacokinetics of hoasca alkaloids in healthy humans

Callaway JC, McKenna DJ et al.

Journal of Ethnopharmacology, 1999
Pharmacology

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I et al.

Archives of Toxicology, 2025
Pharmacology

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher HD, Mueller MJ et al.

Frontiers in Psychiatry, 2024